See Table. Minimum acceptable age for the 1st dose of scheduled vaccines in infants in special circumstances in Catch-up vaccination.

Antigen

Doses needed

Minimum interval between doses

Notes

Diphtheria and tetanus

3 doses

  • Between doses 1 and 2: 4 weeks
  • Between doses 2 and 3: 4 weeks
  • People should receive 1 of the doses as dTpa-containing vaccine and complete the course with dT. This dose would also provide the catch-up dose for pertussis.
  • If dT is not available, use dTpa or dTpa-IPV for all 3 primary doses.

Pertussis

1 dose

  • Not required
  • People ≥10 years of age who did not receive all the pertussis vaccine doses recommended before the age of 10 years only need 1 dose to be considered up to date. This is regardless of the number of previous doses they received before the age of 10 years.
  • A booster dose of pertussis-containing vaccine is routinely recommended for all adolescents aged 11–13 years. Take this into account when planning catch-up for pertussis.

Hepatitis B, if aged 10–19 years

3 paediatric doses

  • Between doses 1 and 2: 1 month
  • Between doses 2 and 3: 2 months

Minimum interval between dose 1 and dose 3 is 4 months.

Hepatitis B, if aged 11–15 years only

2 adult doses

  • 4 months

None

Hepatitis B — if aged ≥20 years

3 adult doses

  • Between doses 1 and 2: 1 month
  • Between doses 2 and 3: 2 months
  • Minimum interval between dose 1 and dose 3 is 4 months.
  • Some people who are immunocompromised are recommended to receive extra doses or vaccines with higher antigen content.

Poliomyelitis

3 doses

  • Between doses 1 and 2: 4 weeks
  • Between doses 2 and 3: 4 weeks

None

Human papillomavirus, if started at 9–14 years of age

2 doses

  • 6 months
  • If there is an interval of <5 months between doses 1 and 2, a 3rd dose is needed at least 12 weeks after the 2nd dose.
  • If there is an interval of <6 months but ≥5 months between doses 1 and 2, a 3rd dose is not needed.
  • People who are immunocompromised need a 3-dose schedule, regardless of age when they start vaccination.

Human papillomavirus, if started at ≥15 years of age

3 doses

  • Between doses 1 and 2: 4 weeks
  • Between doses 2 and 3: 12 weeks

Minimum interval between dose 1 and dose 3 is 5 months.

Measles, mumps and rubella

2 doses

  • Between doses 1 and 2: 4 weeks

None

Meningococcal

1 dose of MenACWY vaccine

  • Not required

The required catch-up dose is specific to routine use of MenACWY vaccine. MenACWY and MenB vaccines are also indicated for people at increased risk of meningococcal disease in alternative schedules. See Meningococcal disease  and Vaccination for special risk groups.

Pneumococcal

Depends on person’s age, Aboriginal and Torres Strait Islander status, and whether they have medical condition(s) associated with an increased risk of invasive pneumococcal disease

  • Varies

See Pneumococcal disease and Vaccination for special risk groups.

Varicella, if aged <14 years

At least 1 dose

  • Between doses 1 and 2: 4 weeks (if 2nd dose is given)
  • Recommended for all non-immune people. People aged <14 years are recommended to receive at least 1 and preferably 2 doses.
  • Children aged <14 years can receive MMRV vaccine.

Varicella, if aged ≥14 years

2 doses

  • 4 weeks
  • 2 doses are recommended for all non-immune people aged ≥14 years.
  • MMRV is not recommended for use in people ≥14 years of age.

Zoster

1 dose if aged ≥60 years

  • Not required
  • Zoster vaccine is recommended for people aged ≥60 years. Routine vaccination of people aged 70–79 years is particularly recommended because it is expected to provide the greatest benefits against herpes zoster and its complications.

dT =diphtheria-tetanus; dTpa = reduced antigen content diphtheria-tetanus-acellular pertussis; IPV = inactivated poliovirus; MenACWY = meningococcal ACWY; MenB = meningococcal B; MMRV = measles-mumps-rubella-varicella

Previous

Table. Catch-up schedule for Haemophilus influenzae type b (Hib) vaccination for children

Next

Table. Clinical features that may help differentiate between a vasovagal episode and anaphylaxis

Last updated: 
5 June 2018
Last reviewed: 
5 June 2018

Definitions

dTpa
diphtheria-tetanus-acellular pertussis vaccine, reduced antigen content formulation
dT
diphtheria-tetanus vaccine for use in adults
IPV
inactivated poliomyelitis vaccine
MMRV
measles-mumps-rubella-varicella